Genetically engineered multivalent proteins for targeted immunotherapy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

mAbs initiated the unprecedented breakthroughs in cancer immunotherapy and are rapidly evolving with multiple therapeutic platforms. One next-generation strategy engineers multivalent proteins that ligate single-chain variable fragments targeting cellular effectors, tumor-associated antigens, and cytokines. These developing therapeutics target and regulate cellular effector bioactivity and significantly improve clinical outcomes.

Original languageEnglish (US)
Pages (from-to)3419-3421
Number of pages3
JournalClinical Cancer Research
Volume22
Issue number14
DOIs
StatePublished - Jul 15 2016

Fingerprint

Immunotherapy
Single-Chain Antibodies
Neoplasm Antigens
Proteins
Cytokines
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Genetically engineered multivalent proteins for targeted immunotherapy. / Talmadge, James E.

In: Clinical Cancer Research, Vol. 22, No. 14, 15.07.2016, p. 3419-3421.

Research output: Contribution to journalArticle

@article{9a566734317a425dbb8275d247739bd2,
title = "Genetically engineered multivalent proteins for targeted immunotherapy",
abstract = "mAbs initiated the unprecedented breakthroughs in cancer immunotherapy and are rapidly evolving with multiple therapeutic platforms. One next-generation strategy engineers multivalent proteins that ligate single-chain variable fragments targeting cellular effectors, tumor-associated antigens, and cytokines. These developing therapeutics target and regulate cellular effector bioactivity and significantly improve clinical outcomes.",
author = "Talmadge, {James E}",
year = "2016",
month = "7",
day = "15",
doi = "10.1158/1078-0432.CCR-16-0246",
language = "English (US)",
volume = "22",
pages = "3419--3421",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Genetically engineered multivalent proteins for targeted immunotherapy

AU - Talmadge, James E

PY - 2016/7/15

Y1 - 2016/7/15

N2 - mAbs initiated the unprecedented breakthroughs in cancer immunotherapy and are rapidly evolving with multiple therapeutic platforms. One next-generation strategy engineers multivalent proteins that ligate single-chain variable fragments targeting cellular effectors, tumor-associated antigens, and cytokines. These developing therapeutics target and regulate cellular effector bioactivity and significantly improve clinical outcomes.

AB - mAbs initiated the unprecedented breakthroughs in cancer immunotherapy and are rapidly evolving with multiple therapeutic platforms. One next-generation strategy engineers multivalent proteins that ligate single-chain variable fragments targeting cellular effectors, tumor-associated antigens, and cytokines. These developing therapeutics target and regulate cellular effector bioactivity and significantly improve clinical outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84978371390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978371390&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-16-0246

DO - 10.1158/1078-0432.CCR-16-0246

M3 - Article

VL - 22

SP - 3419

EP - 3421

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 14

ER -